 |
|
The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
Jin-Hyuk Choi, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Mi Sun Ahn, Young-Taek Oh, O kyu Noh, Se-Hyuk Kim, Tae Hoon Roh, Seung Soo Sheen
Korean J Intern Med. 2022;37(2):434-443. Published online 2022 Feb 16 DOI: https://doi.org/10.3904/kjim.2021.315
|
|
Citations to this article as recorded by
 Efficacy and safety of EGFR-TKI combined with early brain radiotherapy versus TKI alone in patients with EGFR-mutated NSCLC with brain metastases: a systematic review and meta-analysis
Zihan Zeng, Simin Feng, Tinghua Gao, Chengye Chen, Jun Chen, Junliang Chen, Yingni Lian
Clinical Lung Cancer.2025;[Epub] CrossRef Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
BMC Cancer.2024;[Epub] CrossRef
|